Please Wait
Applying Filters...
menu
    • menu
    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-23

    Virtual Booth

    An Enquiry

    Left Arrow
    Right Arrow

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    HbO2 Therapeutics is a leader in the development of human and veterinary hemoglobin-based oxygen carriers (HBOCs), therapies that when intravenously administered, increase the oxygen-carrying capacity of blood. The Company has two core products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine), and Oxyglobin® [hemoglobin glutamer - 200 (bovine)] for human and veterinary use, respectively. In 2001, Hemopure was ap...
    HbO2 Therapeutics is a leader in the development of human and veterinary hemoglobin-based oxygen carriers (HBOCs), therapies that when intravenously administered, increase the oxygen-carrying capacity of blood. The Company has two core products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine), and Oxyglobin® [hemoglobin glutamer - 200 (bovine)] for human and veterinary use, respectively. In 2001, Hemopure was approved in South Africa for the treatment of adult surgical patients who are acutely anemic, for the purpose of eliminating, delaying, or reducing the need for allogeneic red blood cells.

    List your booth number for exhibitions, ask us